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Abstract
Background: In B cell non-Hodgkin lymphoma (B-NHL), rituximab-containing reduced-intensity conditioning
regimens (R-RIC) have been shown to provide favorable outcomes in single-arm studies; however, large multicenter
studies comparing R-RIC and non-rituximab-containing reduced-intensity conditioning regimens (nonR-RIC) have
not been performed. Using the CIBMTR database, we report the outcomes of R-RIC versus nonR-RIC regimens in B-
NHL.
Methods: We evaluated 1401 adult B-NHL patients undergoing allogeneic hematopoietic cell transplantation (allo-
HCT) who received nonR-RIC (n = 1022) or R-RIC (n = 379) regimens. Graft-versus-host disease (GVHD) prophylaxis
was limited to calcineurin inhibitor-based approaches.
Results: Median follow-up of survivors in the R-RIC and nonR-RIC groups was 47 and 37 months, respectively. On
multivariate analysis, no difference was seen between the R-RIC and nonR-RIC cohorts in terms of acute GVHD
grade II–IV (RR = 1.14, 95%CI = 0.83–1.56, p = 0.43) or grade III–IV (RR = 1.16, 95%CI = 0.72–1.89, p = 0.54), chronic
GVHD (RR = 1.15, 95%CI = 0.92–1.46, p = 0.22), non-relapse mortality (RR = 0.90; 95%CI = 0.67–1.22; p = 0.51), relapse/
progression (RR = 0.79; 95%CI = 0.63–1.01; p = 0.055), and mortality (RR = 0.84, 95%CI = 0.69–1.02, p = 0.08) risk.
However, R-RIC was associated with a significantly improved progression-free survival (RR = 0.76; 95%CI 0.62–0.92; p
= 0.006). On subgroup analysis, mortality benefit was noted in the R-RIC group patients not receiving busulfan-
based RIC (RR = 0.76; 95%CI = 0.60–0.96; p = 0.02) and with the use of a higher cumulative rituximab dose (RR = 0.43;
95%CI = 0.21–0.90; p = 0.02).
Conclusion: Our analysis shows that inclusion of rituximab in RIC regimens improves progression-free survival in
patients with B cell NHL. These data supports the use of R-RIC in B-NHL patients undergoing allo-HCT.
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Background
Reduced-intensity conditioning (RIC) regimens currently
account for approximately 40–45% of all allogeneic
transplants performed in the USA [1]. These lower-
intensity regimens rely more heavily on the graft-versus-
tumor effects (exerted by the donor effector cells) to
eradicate the residual disease in transplant recipients.
RIC regimens are generally associated with a lower risk
of procedure-related morbidity and non-relapse mortal-
ity (NRM) rates, thereby extending the option of allo-
geneic hematopoietic cell transplantation (allo-HCT) to
patients with advanced age and/or significant medical
comorbidities.
Considering the median age at diagnosis of patients
with non-Hodgkin lymphomas (NHL) (~66 years), it is
not surprising that RIC regimens now account for the
majority of allo-HCTs performed for lymphomas in the
USA [1]. However, the risk of disease relapse tends to be
generally higher following RIC regimens compared to
myeloablative allo-HCT in NHL [2, 3]. Identification of
RIC approaches with the best risk/benefit ratio (NRM
vs. relapse rate) in NHL remains an unmet medical need.
Disease-specific RIC regimens, incorporating targeted
therapies, can potentially provide improved peri-
transplantation disease control, without increasing the
rates of transplant-related morbidity and mortality. RIC
regimens containing rituximab, an antiCD20 antibody
with antineoplastic activity, have been employed in pa-
tients with B cell NHL [4–8]. Several single-institution
studies incorporating rituximab in RIC regimens for B
cell NHL have reported excellent disease control, with
low rates of toxicity and severe graft-versus-host disease
(GVHD) [4, 7]. However, large, multicenter studies com-
paring outcomes of RIC regimens incorporating rituxi-
mab, against those without rituximab in B cell NHL,
have not been performed. We report here a registry ana-
lysis, comparing outcomes of rituximab-containing RIC
(R-RIC) regimens versus non-rituximab containing RIC
(nonR-RIC) regimens in B cell NHL.
Methods
Data sources
The CIBMTR is a working group of more than 500
transplantation centers worldwide that contribute de-
tailed data on HCT to a statistical center at the Medical
College of Wisconsin (MCW). Participating centers are
required to report all transplantations consecutively, and
compliance is monitored by on-site audits. Computer-
ized checks for discrepancies, physicians’ review of sub-
mitted data, and on-site audits of participating centers
ensure data quality. Observational studies conducted by
the CIBMTR are performed in compliance with all ap-
plicable federal regulations pertaining to the protection
of human research participants. The MCW and National
Marrow Donor Program, Institutional Review Boards ap-
proved this study.
The CIBMTR collects data at two levels: Transplant Es-
sential Data (TED) and Comprehensive Report Form
(CRF) data. TED-data includes disease type, age, gender,
pre-HCT disease stage and chemotherapy-responsiveness,
date of diagnosis, graft type, conditioning regimen, post-
transplant disease progression and survival, development
of a new malignancy, and cause of death. All CIBMTR
centers contribute TED-data. More detailed disease and
pre- and post-transplant clinical information is collected
on a subset of registered patients selected for CRF data by
a weighted randomization scheme. TED- and CRF-level
data are collected pre-transplant, 100-days and 6 months
post-HCT, and annually thereafter or until death. Data for
the current analysis were retrieved from CIBMTR (TED
and CRF) report forms.
Patients
Included in this analysis are adult (≥18 years) patients
with B cell NHL, undergoing their first RIC or non-
myeloablative conditioning (NMA) allo-HCT between
2008 and 2014. Eligible histologies included diffuse large
B cell lymphoma (DLBCL), follicular lymphoma (FL),
mantle cell lymphoma (MCL), and marginal zone
lymphoma (MZL). Eligible donors including either
HLA-identical sibling donors or unrelated donors (URD)
matched at the allele-level at HLA-A, HLA-B, HLA-C
and HLA-DRB1. Peripheral blood or bone marrow was
permitted graft-source. GVHD prophylaxis was limited
to calcineurin inhibitor (CNI)-based approaches. Pa-
tients receiving ex vivo graft manipulation (T cell de-
pleted = 8 or CD34 selected grafts = 28) were not
included. Use of antithymocyte globulin (ATG) during
allo-HCT was not considered as an exclusion. Since
alemtuzumab was used infrequently in patients receiving
rituximab-based RIC (n = 1), these cases were not in-
cluded. Radioimmunotherapy-based RIC regimens were
excluded (n = 26).
Definitions
The intensity of conditioning regimens was defined
using consensus criteria [9]. Complete remission (CR) to
last line of therapy before allo-HCT on CIBMTR forms
is defined as complete resolution of all known areas of
disease on radiographic assessments, while partial remis-
sion (PR) is defined as ≥50% reduction in the greatest
diameter of all sites of known disease and no new sites
of disease [10]. The resistant disease is defined as <50%
reduction in the diameter of all disease sites, or develop-
ment of new disease sites. Disease risk index (DRI) was
defined as reported previously [11].
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Study endpoints
The primary endpoint was overall survival (OS); death from
any cause was considered an event, and surviving patients
were censored at last contact. NRM was defined as death
without evidence of lymphoma progression/relapse; relapse
was considered a competing risk. Progression/relapse was
defined as progressive lymphoma after HCT or lymphoma
recurrence after a CR; NRM was considered a competing
risk. For progression-free survival (PFS), a patient was con-
sidered a treatment failure at the time of progression/relapse
or death from any cause. Patients alive without evidence of
disease relapse or progression were censored at last follow-
up. Acute GVHD [12] and chronic GVHD [13] were graded
using standard criteria. Neutrophil recovery was defined as
the first of three successive days with absolute neutrophil
count (ANC) ≥500/μL after post-transplantation nadir.
Platelet recovery was defined as achieving platelet counts
≥20,000/μL for at least 3 days, unsupported by transfusion.
For neutrophil and platelet recovery, death without the
event was considered a competing risk.
Statistical analysis
The R-RIC cohort was compared against the nonR-RIC co-
hort. Probabilities of PFS and OS were calculated as de-
scribed previously [14]. Cumulative incidence of NRM,
lymphoma progression/relapse, and hematopoietic recovery
were calculated to accommodate for competing risks [15].
Associations among patient-, disease-, and transplantation-
related variables and outcomes of interest were evaluated
using Cox proportional hazards regression. A stepwise
model building approach was used to identify covariates that
influenced outcomes. Covariates with a p < 0.05 were con-
sidered statistically significant. The proportional hazards as-
sumption for Cox regression was tested by adding a time-
dependent covariate for each risk factor and each outcome.
Interactions between the main effect and significant covari-
ates were examined (in particular disease histology, GVHD
prophylaxis regimen, and remission status at HCT), and
none were found. Results are expressed as relative risks
(RR). The center effect was examined using the random ef-
fect score test [16] for OS, PFS, relapse, and NRM. The mar-
ginal Cox proportional hazards model was used to account
for the center effect on chronic GVHD, NRM, relapse, PFS,
and OS [17]. Generalized linear mixed model with the logit
link function was used to account for the center effect on
acute GVHD II-IV and III-IV. The variables considered in
multivariate analysis are shown in Additional file 1: Table
S1. All statistical analyses were performed using SAS version
9.4 (SAS Institute Inc., Cary, NC).
Results
Baseline characteristics
The patient population was divided into two groups; 379
patients receiving rituximab as part of RIC regimens
were included in the R-RIC group, while 1022 patients
not receiving rituximab with conditioning constituted
the nonR-RIC cohort. The baseline patient-, disease-,
and transplantation-related characteristics are shown in
Table 1. There was no significant difference between the
two groups in terms of patient age, gender, race, Kar-
nofsky performance score (KPS), HCT-comorbidity
index (HCT-CI), interval between diagnosis and allo-
HCT, median lines of prior therapy, remission status at
HCT, total body irradiation (TBI) use in conditioning,
donor type, donor-recipient sex match, and donor-
recipient CMV serostatus. DLBCL was the most com-
mon histology in the nonR-RIC group (44%) while FL
was the most common histology (37%) in the R-RIC
group (p < 0.001). The proportion of patients with inter-
mediate DRI (50 vs. 40%; p = 0.03) and history of a prior
autologous HCT (43 vs. 26%; p < 0.001) was higher in
the nonR-RIC cohort. Fludarabine/busulfan (Flu/Bu) ±
total body irradiation (TBI) was the most common con-
ditioning in the nonR-RIC group (35%) while fludara-
bine/cyclophosphamide (Flu/Cy) ± TBI in the R-RIC
group (54%). CNI ± methotrexate-based GVHD prophy-
laxis was more common in the R-RIC group (55 vs 38%;
p < 0.001). The graft source was mainly peripheral blood
in both groups (95% [n = 970) vs. 98% [n = 371] in the
nonR-RIC and R-RIC groups, respectively). Median
follow-up of survivors was 37 months (range, 2–
79 months) in the nonR-RIC group and 47 months
(range, 6–89 months) in the R-RIC group.
Hematopoietic recovery
The cumulative incidence of neutrophil recovery at day
28 was 97% (95%CI 96–98) in the nonR-RIC group com-
pared to 98% (95%CI 96–99) in the R-RIC group (p =
0.51). The day-28 cumulative incidence of platelet recov-
ery in similar order was 90 vs. 90% (p = 0.66; Table 2).
Acute and chronic GVHD
On univariate analysis, the cumulative incidence of
grade II–IV acute GVHD at day 180 (Table 2) in the
nonR-RIC cohort was 37% (95%CI 34–40), compared to
43% (95%CI 38–48) in the R-RIC group (p = 0.03). The
corresponding rates of grades III–IV acute GVHD were
13% (95%CI 11–16) vs. 16% (95%CI 12–19) in the nonR-
RIC and R-RIC groups, respectively, (p = 0.29). There
was a significant center effect for grade II–IV acute
GVHD (p = 0.004) and grade III–IV acute GVHD (p =
0.01). On multivariate analysis (Table 3), after adjusting
for the center effect, R-RIC was not associated with a
higher risk of grade II–IV (RR = 1.14, 95%CI = 0.83–1.56,
p = 0.43) or grade III–IV (RR = 1.16, 95%CI = 0.72–1.89,
p = 0.54) acute GVHD, relative to the nonR-RIC cohort.
Grade II–IV acute GVHD was associated with a signifi-
cantly high NRM (RR = 2.88, p < 0.0001), inferior PFS
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Age at HCT, years
Median (range) 57 (18–74) 56 (28–74) 0.32
>65 142 (14) 45 (12) 0.07
Male gender 667 (65) 248 (65) 0.95
Race 0.55
Caucasian 918 (90) 359 (95)
African American 24 (2) 8 (2)
Others 17 (2) 10 (3)
Missing 63 (6) 2 (<1)
Karnofsky performance score ≥90 622 (61) 235 (62) 0.24
HCT-CI 0.58
0 331 (32) 141 (37)
1–2 301 (29) 115 (30)
≥3 326 (32) 120 (32)
Missing 64 (6) 3 (<1)
Histology <0.001
Follicular lymphoma 268 (26) 142 (37)
Diffuse large B cell lymphoma 452 (44) 124 (33)
Mantle cell lymphoma 274 (27) 106 (28)
Marginal zone lymphoma 28 (3) 7 (2)
Interval from diagnosis to HCT, months 0.73
Median (range) 36 (2-386) 39 (3-310)
Median lines of therapy before HCT 3 (1-9) 3 (1-8) 0.54
Remission status at HCT 0.19
Complete remission 459 (45) 147 (39)
Partial remission 421 (41) 169 (45)
Chemorefractory 125 (12) 59 (16)
Untreated 8 (<1) 2 (<1)
Unknown 9 (<1) 2 (<1)
Disease risk index at HCT 0.003
Low 405 (40) 184 (49)
Intermediate 509 (50) 151 (40)
High 99 (10) 42 (11)
Missing 9 (<1) 2 (<1)
History of prior autologous HCT 436 (43) 99 (26) <0.001
Conditioning regimen <0.001
Flu/Bu ± TBI 360 (35) 21 (5)
Flu/Cy ± TBI 156 (15) 207 (54)
Flu/Mel ± TBI 271 (27) 55 (15)
2 Gy TBI ± Flu 196 (19) 40 (11)
BEAM or similar 39 (4) 56 (15)
TBI in conditioning 265 (26) 90 (24) 0.40
Epperla et al. Journal of Hematology & Oncology  (2017) 10:117 Page 4 of 12
(RR = 1.6, p < 0.0001), and OS (RR = 1.93, p < 0.0001) in
our study.
On univariate analysis, the cumulative incidence of
chronic GVHD at 1 year (Table 2) after nonR-RIC trans-
plant was 44% (95%CI 41–48) compared to 41% (95%CI
36–47) in the R-RIC group (p = 0.32). There was signifi-
cant center effect noted for chronic GVHD (p < 0.0001).
After adjusting for center effect, multivariate analysis
(Table 3) showed no significant difference in the risk of
chronic GVHD in the recipients of R-RIC transplant,
(RR = 1.15, 95%CI = 0.92–1.46, p = 0.22) relative to the
nonR-RIC group (Fig. 1a).
NRM and relapse
The 1-year NRM rate in the nonR-RIC group was 14%
(95%CI = 12–16) compared to 13% (95%CI = 10–17) in
the R-RIC group (p = 0.78; Table 2). There was a signifi-
cant center effect noted for NRM (p = 0.005). On multi-
variate analysis, after adjusting for the center effect, R-
RIC was not associated with a higher risk of NRM (RR
= 0.90, 95%CI = 0.67–1.22, p = 0.51) (Fig. 1b). Other
factors independently associated with the risk of NRM
are shown in the Additional file 1: Table S2.
The cumulative incidence of relapse/progression at
3 years was 32% (95%CI = 29–35) and 24% (95%CI = 20–
29) in the nonR-RIC and R-RIC groups, respectively, (p
= 0.005; Table 2). On multivariate analysis, the risk of re-
lapse/progression was not significantly different between
the two groups (RR = 0.79, 95%CI 0.63–1.01, p = 0.055)
(Table 3) (Fig. 1c). Other factors independently associ-
ated with the risk of relapse/progression are shown in
the Additional file 1: Table S2.
Progression-free survival
The 3-year PFS was significantly better in the R-RIC
group (56%; 95%CI = 51–61) compared to the nonR-RIC
group (47%; 95%CI = 44–50; p = 0.005; Table 2). On
multivariate analysis (Table 3), relative to the nonR-RIC
group, the R-RIC was associated with a significantly im-
proved PFS (RR = 0.76, 95%CI = 0.62–0.92, p = 0.006)
(Fig. 1d). Other factors independently associated with
the PFS are shown in the Additional file 1: Table S2.
Table 1 Baseline patient characteristics of patients with NHL reported to the CIBMTR from 2008 to 2014 (Continued)
ATG in conditioning 191 (19) 75 (20) 0.64
Graft source 0.02
Bone marrow 52 (5) 8 (2)
Peripheral blood 970 (95) 371 (98)
Donor type 0.10
HLA-identical sibling 565 (55) 191 (50)
URD 8/8 457 (45) 188 (50)
Donor-recipient sex match 66 (36) 227 (46) 0.62
Male-male 434 (42) 168 (44)
Male-female 222 (22) 89 (23)
Female-male 233 (23) 80 (21)
Female-female 133 (13) 42 (11)
Donor/recipient CMV status 0.14
Both negative 305 (30) 112 (30)
Either donor/recipient+ 711 (70) 259 (68)
Missing 6 (<1) 8 (2)
Graft-versus-host disease prophylaxis <0.001
Calcineurin inhibitor + MTX ± othersa
(except MMF and sirolimus)
392 (38) 207 (55)
Calcineurin inhibitor + MMF ± othersa
(except sirolimus)
402 (39) 95 (25)
Calcineurin inhibitor + sirolimus ± othersa 200 (20) 75 (20)
Calcineurin inhibitor alone 28 (3) 2 (<1)
Median follow-up of survivors (range), months 37 (2–79) 47 (6–89)
Number of centers that reported only nonR-RIC cases = 76, R-RIC cases = 3, and both (nonR-RIC and R-RIC) cases = 35
Abbreviations: ATG antithymocyte globulin, Bu busulfan, CMV cytomegalovirus, Cy cyclophosphamide, Flu fludarabine, HCT hematopoietic cell transplantation, HCT-
CI HCT-comorbidity index, Mel melphalan, MMF mycophenolate mofetil, MTX methotrexate, TBI total body irradiation, RIC reduced-intensity conditioning
aFor details, refer to Additional file 1: Table S8
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Overall survival
The 3-year OS in the nonR-RIC and R-RIC groups was 56%
(95%CI 53–59) and 64% (95%CI 59–68), respectively, p =
0.01 (Table 2). There was a significant center effect noted
for OS (p= 0.005). On multivariate analysis (Table 3), after
adjusting for the center effect, R-RIC was not associated
with a significantly reduced risk of mortality (RR = 0.84,
95%CI = 0.69–1.02, p= 0.08) relative to nonR-RIC allo-HCT
(Fig. 1e). Other factors independently associated with mor-
tality risk are shown in the Additional file 1: Table S2.
Rituximab and disease histology
The interaction between the main effect (i.e., R-RIC vs.
RIC) and disease histology (DLBCL, FL, MCL, and MZL)
was checked for each outcome. It was not significant for
grade II–IV acute GVHD (p = 0.18), grade III–IV acute
GVHD (p = 0.64), chronic GVHD (p = 0.99), relapse (p =
0.96), NRM (p = 0.70), PFS (p = 0.84), and OS (p = 0.53)
(For details of histology-specific multivariate models
please refer to page 10 of Additional file 1: Tables S3-S5).
The subset analysis for chemorefractory patients at the
time of HCT is given in Additional file 1: Table S6.
Prior autologous transplant
On multivariate analysis, independent of the type of RIC
transplant (R or nonR), prior auto-HCT was associated
with higher NRM (HR = 1.38, 95%CI 1.07–1.78, p =
0.01), inferior PFS (HR = 1.28, 95%CI 1.08–1.51, p =
0.004), and OS (HR = 1.22, 95%CI 1.02–1.46, p = 0.02)
(Additional file 1: Table S2).
Pre-transplant rituximab
Among nonR-RIC and R-RIC groups, 149 and 89 cases
on the CRF track had details of pre-transplant





Outcomes N eval Prob (95%CI) N eval Prob (95%CI) p value
ANC recovery >500/uL 1013 379
28 days 97 (96–98)% 98 (96–99)% 0.51
100 days 99 (98–99)% 99 (97–100)% 0.99
Platelet recovery≥ 20/uL 986 378
28 days 90 (88–92)% 90 (87–93)% 0.66
100 days 96 (94–97)% 96 (93–97)% 0.79
Acute GVHD (II IV) 1004 377
180 days 37 (34–40)% 43 (38–48)% 0.03
Acute GVHD (III IV) 1004 377
180 days 13 (11–16)% 16 (12–19)% 0.29
Chronic GVHD 982 369
1 year 44 (41–48)% 41 (36–47)% 0.32
2 years 53 (50–57)% 53 (47–58)% 0.79
NRM 988 367
1 year 14 (12–16)% 13 (10–17)% 0.78
3 years 21 (18–24)% 20 (16–24)% 0.68
Relapse/progression 988 367
1 year 26 (23–29)% 19 (15–23)% 0.004
3 years 32 (29–35)% 24 (20–29)% 0.005
PFS 988 367
1 year 60 (57–63)% 68 (63–72)% 0.007
3 years 47 (44–50)% 56 (51–61)% 0.005
Mortality (inverse of OS) 1022 379
1 year 70 (67–73)% 76 (71–80)% 0.04
3 years 56 (53–59)% 64 (59–68)% 0.01
Probabilities of neutrophil and platelet recovery, platelet recovery, acute GVHD, chronic GVHD, treatment-related mortality, and progression/relapse were calcu-
lated using the cumulative incidence estimate. Progression-free survival and overall survival was calculated using the Kaplan-Meier product limit estimate
Abbreviations: ANC absolute neutrophil count, GVHD graft-versus-host disease, PROB probability, CI confidence interval, N eval number evaluable, NRM non-relapse
mortality, PFS progression free survival, RIC reduced-intensity conditioning, OS overall survival
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treatments available. Among this subset, 54% (n = 80) of
nonR-RIC and 64% (n = 57) of R-RIC patients received
rituximab as a part of last line therapy prior to trans-
plantation (p = 0.12).
Causes of death
At last follow-up, 43% (n = 444) of nonR-RIC and 37%
(n = 139) of R-RIC transplant recipients had died (Add-
itional file 1: Table-S6). The most common cause of
death in both cohorts was recurrent/progressive lymph-
oma; 18% (n = 186) and 14% (n = 52) in the nonR-RIC
and R-RIC groups, respectively. GVHD was the cause of
death in 4% (n = 36) and 6% (n = 21) of recipients of
nonR-RIC and R-RIC transplant, respectively. Infectious
complications led to the death of 3% (n = 29) in nonR-
RIC group and 3% (n = 13) in R-RIC group. Among the
nonR-RIC and R-RIC groups, 157 and 89 cases on the
CRF track had detailed post-transplant infectious disease
data available. Among this subset, 26% (n = 41) of nonR-
RIC and 20% (n = 18) of R-RIC patients had CMV reacti-
vation (p = 0.20) and 1% (n = 2) of nonR-RIC and 2% (n
= 2) of R-RIC patients had EBV reactivation (p = 0.60).
Neither of the groups (R-RIC or nonR-RIC) had any
HBV reactivation cases.
Subset analysis
Among the 381 patients receiving Flu/Bu-based RIC,
only 21 patients (5%) received rituximab-based condi-
tioning. Results of multivariate analysis after excluding
the patients receiving Flu/Bu-based conditioning are
shown in Table 4. These results were generally in line
with multivariate analysis of overall study population
and showed that relative to non-R-RIC group, the R-RIC
group was associated with no difference in grade III–IV
acute GVHD (RR = 0.89, 95%CI = 0.59–1.34, p = 0.58),
chronic GVHD (RR = 1.07, 95%CI = 0.87–1.30, p = 0.51),
NRM (RR = 0.79, 95%CI = 0.57–1.08, p = 0.14), or pro-
gression/relapse (RR = 0.82, 95%CI = 0.64–1.06, p = 0.13),
and the R-RIC significantly improved PFS (RR = 0.002,
95%CI = 0.60–0.89, p = 0.002). However, unlike the over-
all multivariate model, this subgroup analysis showed a
significantly reduced risk of mortality with R-RIC (RR =
0.76, 95%CI = 0.60–0.96, p = 0.02), relative to the nonR-
RIC cohort.
Effect of cumulative rituximab dose in conditioning
The cumulative (or total) dose of rituximab administered
with allo-HCT conditioning varies significantly across
different centers. To assess the impact of cumulative
Table 3 Multivariate analysis results





Acute GVHD (grades 2–4)a
Non-rituximab RIC 1004 1 0.43
Rituximab-containing RIC 377 1.14 0.83 1.56
Acute GVHD (grades 3–4)a
Non-rituximab RIC 1004 1 0.54
Rituximab-containing RIC 377 1.16 0.72 1.89
Chronic GVHD
Non-rituximab RIC 982 1 0.22
Rituximab-containing RIC 369 1.15 0.92 1.46
Non-relapse mortality
Non-rituximab RIC 988 1 0.51
Rituximab-containing RIC 367 0.90 0.67 1.22
Progression/relapse
Non-rituximab RIC 988 1 0.055
Rituximab-containing RIC 367 0.79 0.63 1.01
PFS
Non-rituximab RIC 988 1 0.006
Rituximab-containing RIC 367 0.76 0.62 0.92
Mortality
Non-rituximab RIC 1022 1 0.08
Rituximab-containing RIC 379 0.84 0.69 1.02
Abbreviations: GVHD graft-versus-host disease, CI confidence interval, RIC reduced-intensity conditioning
aAcute GVHD models used logistic regression
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Table 4 Multivariate analysis results (excluding Fludarabine/Busulfan-based conditioning regimens)





Acute GVHD (grades 3–4)a
Non-rituximab RIC 647 1 0.58
Rituximab-containing RIC 356 0.89 0.59 1.34
Chronic GVHD
Non-rituximab RIC 635 1 0.51
Rituximab-containing RIC 349 1.07 0..87 1.30
Non-relapse mortality
Non-rituximab RIC 638 1 0.14
Rituximab-containing RIC 346 0.79 0.57 1.08
Progression/relapse
Non-rituximab RIC 638 1 0.13
Rituximab-containing RIC 346 0.82 0.64 1.06
PFS
Non-rituximab RIC 638 1 0.002
Rituximab-containing RIC 346 0.73 0.60 0.89
Mortality
Non-rituximab RIC 662 1 0.02
Rituximab-containing RIC 358 0.76 0.60 0.96
Abbreviations: GVHD graft-versus-host disease, RIC reduced-intensity conditioning
aAcute GVHD models used logistic regression
Fig. 1 Adjusted transplantation outcomes of patients receiving R-RIC (interrupted lines) and nonR-RIC (solid line) regimens. a Cumulative inci-
dence of chronic graft-versus-host-disease. b Cumulative incidence of non-relapse mortality. c Cumulative incidence of lymphoma relapse/pro-
gression. d Progression-free survival. e Overall survival
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rituximab dose on HCT outcomes, we divided the R-
RIC cohort patients into three groups based on the cu-
mulative rituximab dose received during
RIC—<1000 mg/m2 (low; n = 214), 1000–1999 mg/m2
(intermediate; n = 113), and 2000–3375 mg/m2 (high; n
= 47). On multivariate analysis (Table 5), there was a re-
duced risk of chronic GVHD with the intermediate ri-
tuximab dose (RR = 0.64; 95%CI 0.46–0.90, p = 0.01)
relative to the low dose rituximab group. High dose ri-
tuximab was associated with a reduced risk of NRM
(RR = 0.18; 95%CI 0.04–0.75; p = 0.02) and overall mor-
tality (RR = 0.43; 95%CI 0.21–0.90; p = 0.02), relative to
the low dose group.
Discussion
Prospective randomized studies comparing the outcomes
of R-RIC and nonR-RIC in B cell NHL have not been
performed. Here, we performed a registry analysis of B
cell NHL patients receiving either rituximab-based or
nonR-RIC regimens for allo-HCT, and make several
important observations. First rates of hematopoietic re-
covery, relapse risk, and NRM were comparable between
R-RIC and nonR-RIC allo-HCT. Second, R-RIC was not
associated with a higher risk of either grade II–IV or
grade III–IV acute GVHD and chronic GVHD. Third,
there was a significantly superior PFS with R-RIC regi-
mens, but in the overall study population, OS was simi-
lar. Finally, in the subset analysis, there was a survival
benefit in favor of R-RIC regimens (after excluding Flu/
Bu-based conditioning regimens) and a higher cumula-
tive rituximab dose was associated with a reduced risk of
NRM and improved survival.
In our study, R-RIC group was not associated with a
higher risk of grade II–IV or grade III–IV acute GVHD
compared to the nonR-RIC cohort. Our analysis also did
not show any difference in the risk of chronic GVHD
between the two groups. Previous studies using R-RIC
have generally shown the rates of chronic GVHD at
1 year to be around 50–60% (Additional file 1: Table S7)
[4–6, 8]. Notably, some retrospective and one
Table 5 Effect of cumulative rituximab dose on outcomes




p value Overall p value
Chronic GVHD
Rituximab dose (mg/m2)
<1000 208 1 0.03
1000–1999 110 0.64 0.46 0.90 0.01
2000–3375 46 0.92 0.62 1.36 0.67
Non-relapse mortality
Rituximab dose (mg/m2)
<1000 208 1 0.06
1000–1999 109 0.90 0.54 1.51 0.70
2000–3375 45 0.18 0.04 0.75 0.02
Progression/relapse
Rituximab dose (mg/m2)
<1000 208 1 0.90
1000–1999 109 1.01 0.63 1.61 0.97
2000–3375 45 0.85 0.40 1.78 0.66
PFS
Rituximab dose (mg/m2)
<1000 208 1 0.21
1000–1999 109 0.99 0.70 1.39 0.94
2000–3375 45 0.56 0.30 1.07 0.08
Mortality
Rituximab dose (mg/m2)
<1000 214 1 0.052
1000–1999 113 1.10 0.76 1.59 0.63
2000–3375 47 0.43 0.21 0.90 0.02
Abbreviations: GVHD graft-versus-host disease
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prospective phase II study using a prolonged rituximab
administration schedule post allo-HCT have suggested
reduced risk of chronic GVHD [7, 18, 19]. However, a
randomized trial did not show any reduction in chronic
GVHD with post allo-HCT administration of rituximab.
Of note, all patients in that study received myeloablative
conditioning regimens [20]. A recent single-center retro-
spective study comparing fludarabine, cyclophospha-
mide, and rituximab (FCR) RIC to Flu/Bu (without
rituximab) [21] reported lower rates of chronic GVHD
and improved OS with R-RIC. However, in that study,
all the patients in the FCR group received tacrolimus/
methotrexate as GVHD prophylaxis, while those in the
Flu/Bu group received tacrolimus/mycophenolate mofe-
til as GVHD prophylaxis that confounds the assessment
of rituximab’s impact on the rates of chronic GVHD and
survival.
Single-arm studies have shown excellent survival out-
comes with R-RIC in B cell NHL [4, 8, 21]. Additional
file 1: Table S7 summarizes the studies that looked at
the addition of rituximab to RIC backbone in an effort
to improve the outcomes. The current study is the first
multicenter validation of these results, wherein there
was a significant improvement in PFS in R-RIC group
compared to the nonR-RIC group. Of note, in our study,
the OS benefit emerged in the subset analysis excluding
Flu/Bu patients. The fact that Flu/Bu was consistently
associated with the lowest risk of NRM and improved
PFS and OS (Additional file 1: Table S2) and that only
5% of Flu/Bu patients got R-RIC in our study prompted
us to perform a subgroup multivariate analysis after ex-
cluding this conditioning approach. Whether the sur-
vival benefit that emerged in the non-Flu/Bu type R-RIC
regimens also exists for Flu/Bu-based regimens requires
further investigation.
In the recently reported BMT CTN 0701 study, OS
was significantly better among patients who achieved a
higher serum concentration of rituximab versus those
with a lower serum concentration at day 28 [8]. The as-
sociation between rituximab dose and serum rituximab
concentration is well known [22]. In line with the obser-
vations made in BMT CTN 0701, in the current analysis,
we observed that the patients who received a higher cu-
mulative rituximab dose (a possible surrogate for higher
serum concentrations) had better OS. We advise caution
in interpreting the data of reduced mortality and NRM
with higher cumulative rituximab dose in our study,
given the small sample size (n = 45), the observed wide
confidence intervals, and the non-significant overall p
value of the model (Table 5). Limited data suggest that
rituximab in conditioning or its early application post
allo-HCT might be associated with prolonged life-
threatening cytopenias [23]. In our study, rituximab use
was not associated with delayed neutrophil recovery or
fatal infections. Mortality due to GVHD was also com-
parable between the two groups. Four percent of deaths
in the nonR-RIC group were due to GVHD as opposed
to 6% in the R-RIC group (Additional file 1: Table S6).
Unfortunately, one of the limitations of the registry
analysis is that we only capture the cumulative rituximab
dose (at conditioning) and do not capture the exact dos-
ing schedule. Additionally, only a small number of pa-
tients (n = 36) received post-transplant rituximab,
thereby limiting the ability to assess the impact of post-
transplant rituximab on the outcomes.
Conclusions
Our analysis is the largest comparative study evaluating
outcomes of R-RIC versus nonR-RIC in B cell NHL pa-
tients. Although there was an increase in the risk of
grade II–IV acute GVHD with R-RIC regimens, there
was no increase in the risk of grade III–IV acute GVHD
or chronic GVHD. There was a significant improvement
in PFS with R-RIC allo-HCT in our study. Survival bene-
fit was noted in the R-RIC group after exclusion of Flu/
Bu conditioning regimen. Additionally, higher cumula-
tive rituximab dose was associated with significantly im-
proved survival. In the absence of randomized data, our
results suggest that R-RIC should be considered as the
preferred conditioning regimen for B cell lymphomas.
Our encouraging data warrants confirmation in a ran-
domized trial setting.
Additional file
Additional file 1: Table S1. Variables tested in Cox proportional hazards
regression models. Table S2. Complete multivariate analysis results.
Table S3. Multivariate analysis results for follicular lymphoma. Table S4.
Multivariate analysis results for mantle cell lymphoma. Table S5.
Multivariate analysis results for diffuse large B cell lymphoma. Table S6.
Univariate analysis—chemorefractory patients. Table S7. Causes of death.
Table S8. Studies incorporating rituximab to allo-HCT conditioning regi-
mens in B cell NHL (DOCX 81 kb)
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